Cronograma de promoção Immunocore Holdings plc
Agenda avançada
Gráfico simples
Sobre a empresa Immunocore Holdings plc
Immunocore Holdings Limited, биотехнологическая компания поздней стадии, разрабатывает иммунотерапию для лечения онкологических, инфекционных и аутоиммунных заболеваний. Ведущим онкологическим терапевтическим кандидатом компании является тебентафусп, который проходит рандомизированное клиническое исследование III фазы у пациентов с ранее нелеченой метастатической увеальной меланомой, раком, который, как исторически доказано, нечувствителен к другим иммунотерапевтическим средствам. mais detalhesIPO date | 2021-02-05 |
---|---|
ISIN | US45258D1054 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Сайт | https://www.immunocore.com |
Цена ао | 29.41 |
Alteração de preço por semana: | +13.71% (29.02) |
---|---|
Alteração de preço por mês: | +9.2% (30.22) |
Alteração de preço em 3 meses: | -0.9901% (33.33) |
Mudança de preço em seis meses: | -16.88% (39.7) |
Mudança de preço por ano: | -54.23% (72.1) |
Mudança de preço em 3 anos: | +47.78% (22.33) |
Mudança de preço desde o início do ano: | +15.14% (28.66) |
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
Instituições | Volume | Compartilhar, % |
---|---|---|
RTW Investments LP | 6096387 | 12.24 |
Wellington Management Group, LLP | 4312611 | 8.66 |
Price (T.Rowe) Associates Inc | 2944574 | 5.91 |
Rock Springs Capital Management, LP | 2661507 | 5.34 |
Baker Brothers Advisors, LLC | 2520731 | 5.06 |
FMR, LLC | 1696386 | 3.41 |
Paradigm Biocapital Advisors LP | 1453883 | 2.92 |
Bellevue Group AG | 976054 | 1.96 |
General Atlantic, L.P. | 950000 | 1.91 |
Morgan Stanley | 917063 | 1.84 |
ETF | Compartilhar, % | Rentabilidade para o ano, % | Dividendos, % |
---|---|---|---|
Virtus LifeSci Biotech Products ETF | 1.24883 | 36.79 | 0.13953 |
Range Cancer Therapeutics ETF | 0.78301 | 47.24 | 0.11955 |
Future Tech ETF | 0.12499 | 426.34 | 0.8416 |
Principal Healthcare Innovators ETF | 0.12499 | 618.5 | 0.8416 |
Invesco Nasdaq Biotechnology ETF | 0.12304 | 28.58 | 0.8565 |
ProShares Ultra Nasdaq Biotechnology | 0.08533 | 51.7 | 0.85651 |
Goldman Sachs Innovate Equity ETF | 0.06941 | 29.66 | 1.20987 |
SPDR Portfolio Developed World ex-US ETF | 0.0075 | 5.29 | 3.28401 |
Supervisor | Cargo | Pagamento | Ano de nascimento |
---|---|---|---|
Dr. Bahija Jallal Ph.D. | CEO & Executive Director | 1.42M | 1961 (64 ano) |
Ms. Annelise Vuidepot Ph.D. | Senior VP, CTO and Research & UK Site Lead | N/A | |
Clayton Robertson | Head of Investor Relations | N/A | |
Mr. Brian R. Di Donato M.B.A. | Executive VP, CFO & Strategy | N/A | 1967 (58 anos) |
Ms. Lily Margaret Hepworth | Senior VP, General Counsel & Company Secretary | N/A | 1983 (42 ano) |
Mr. John Trainer M.B.A. | SVP & Chief Operating Officer | N/A | 1974 (51 ano) |
Mr. John Goll III | SVP, Finance & Chief Accounting Officer | N/A | |
Mr. Sean D. Buckley | VP & Chief Information Officer | N/A | 1983 (42 ano) |
Ms. Tina St. Leger | Chief Human Resources Officer | 1968 (57 anos) | |
Dr. David Berman M.D., Ph.D. | Executive Vice President of Research & Development | 1971 (54 ano) |
Endereço: United Kingdom, Abingdon OX RY, 92 Park Drive - abrir no Google Maps, abrir mapas Yandex
Site: https://www.immunocore.com
Site: https://www.immunocore.com